

## Research Summary

Jazz Pharmaceuticals sponsored this clinical study and would like to thank everyone who participated in studying Vyxeos liposomal (JZP351).

Acute myeloid leukemia (AML) is a blood and bone marrow cancer. Patients who have AML and have received Vyxeos liposomal (JZP351) as treatment were asked to participate in the study. The study is an observational study. Observational studies do not provide any study medicine to participants. The study only collected data from the medical records of participants during the time they were taking Vyxeos liposomal (JZP351) from their regular doctor. The data collected may help researchers learn more about the benefits and risks of taking Vyxeos liposomal (JZP351).

A total of 147 male and female participants with an average age of 60 years participated in the clinical study across 15 centers in the United Kingdom (UK) between January 2022 to May 2022.

## Summary of Results

### What was the purpose of the study?

The 2 main questions the researchers wanted to answer in this study were:

- How many participants experienced a complete response while taking Vyxeos liposomal (JZP351)?
- What is the overall survival of participants after they took Vyxeos liposomal (JZP351)?

These questions were answered by looking at participants' medical records when they took Vyxeos liposomal (JZP351). Complete response is when the bone marrow and blood count return to normal. Overall survival is measured as the median length of time from the date participants started taking Vyxeos liposomal (JZP351) to the time of reported death. Median is the middle value from all reported periods of time arranged from shortest to longest.

### What were the results of the study?

The results of this study show that a complete response was achieved by most participants while taking Vyxeos liposomal (JZP351). Of the 147 participants, 73 (52.9%) participants achieved a complete response. The overall survival is 1.1 years.

### What medical problems (side effects) did the participants have?

Only serious side effects were collected for this study. A side effect is considered serious when it is life-threatening, causes lasting problems, or requires hospital care. Of the 147 participants, 108 (74.5%) participants reported serious side effects while they were taking Vyxeos liposomal (JZP351). 16 participants died while they were taking Vyxeos liposomal (JZP351).

This summary only shows the results of this one clinical study. Other clinical studies may have different results. Clinical studies with Vyxeos liposomal (JZP351) may be ongoing or planned. Additional information can be found on the following website:

- [Clinicaltrials.gov](https://clinicaltrials.gov) – Search for NCT05169307

Further inquiries can be sent to [jazzpharma@medcomsol.com](mailto:jazzpharma@medcomsol.com). This summary was created in July 2023. This summary does not include any information available after this date.